-+ 0.00%
-+ 0.00%
-+ 0.00%
Pharmaceutical Juno-B (02126) plans to discount about 2.97% and issue a total of about 61.185,500 subscription shares to raise HK$160 million
Share
Listen to the news

According to Zhitong Finance App News, Yao Ming Juno-B (02126) announced that on November 15, 2026, the company signed a subscription agreement with China Hongqiao Holdings Limited or its designated entity and Novo Vista Limited Partnership to issue a total of approximately 61.185,500 subscription shares, HK$2.615 per share, a discount of approximately 2.97% from the closing price of HK$2,695 per share on the closing price reported by the Stock Exchange on the last trading day.

The company plans to use the total net proceeds from the subscription for the following purposes: about 40% to promote R&D of the CAR-T product pipeline (including JWCAR306 and other candidate products) within the Group, covering researcher-initiated testing (IIT), manufacturing process development and optimization, IND support research and other related R&D activities; about 30% to support the Group's own CAR-T product pipeline (including JWCAR201 and JWCAR239 (a dual-target, dual-armored CD19/CD20 CAR-T candidate product), focusing on research and development Promote ongoing and planned clinical research, generate clinical data, IND support research and manufacturing process optimization; approximately 20% is used to support the continuous development and upgrading of the Group's technology platform and manufacturing capacity, including the purchase, replacement and upgrade of manufacturing and laboratory equipment, and the improvement of existing manufacturing facilities and related infrastructure; and about 10% is used to support the Group's working capital requirements and general corporate uses.


Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending